ALX ONCOLOGY HOLDINGS INC Increase (Decrease) in Due from Related Parties, Current
ALX ONCOLOGY HOLDINGS INC (ALXO) reported Increase (Decrease) in Due from Related Parties, Current of -$536.00 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2023-03-09.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent · last filed 2023-03-09
- ALX ONCOLOGY HOLDINGS INC increase (decrease) in due from related parties, current for the quarter ending 2020-12-31 was -$527.00K.
- ALX ONCOLOGY HOLDINGS INC increase (decrease) in due from related parties, current for the quarter ending 2020-09-30 was $0.00.
- ALX ONCOLOGY HOLDINGS INC increase (decrease) in due from related parties, current for the quarter ending 2020-06-30 was -$664.00K.
- ALX ONCOLOGY HOLDINGS INC increase (decrease) in due from related parties, current for the quarter ending 2020-03-31 was $655.00K.
- ALX ONCOLOGY HOLDINGS INC increase (decrease) in due from related parties, current for fiscal 2020 was -$536.00K.
- ALX ONCOLOGY HOLDINGS INC increase (decrease) in due from related parties, current for fiscal 2019 was -$396.00K, a 142.49% decline from fiscal 2018.
- ALX ONCOLOGY HOLDINGS INC increase (decrease) in due from related parties, current for fiscal 2018 was $932.00K.
| Period end | Increase (Decrease) in Due from Related Parties, Current 3 month | Increase (Decrease) in Due from Related Parties, Current 6 month | Increase (Decrease) in Due from Related Parties, Current 9 month | Increase (Decrease) in Due from Related Parties, Current 12 month |
|---|---|---|---|---|
| 2020-12-31 | -$527.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$527.00K derived: sum of 2 quarters · filed 2023-03-09 | -$1.19M derived: sum of 3 quarters · filed 2023-03-09 | -$536.00K 10-K · filed 2023-03-09 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$664.00K derived: sum of 2 quarters · filed 2021-11-12 | -$9.00K 10-Q · filed 2021-11-12 | -$819.00K derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | -$664.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$9.00K 10-Q · filed 2021-08-12 | -$819.00K derived: sum of 3 quarters · filed 2022-02-28 | -$823.00K derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $655.00K 10-Q · filed 2021-05-17 | -$155.00K derived: sum of 2 quarters · filed 2022-02-28 | -$159.00K derived: sum of 3 quarters · filed 2022-02-28 | |
| 2019-12-31 | -$810.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$814.00K derived: sum of 2 quarters · filed 2022-02-28 | -$396.00K 10-K · filed 2022-02-28 | |
| 2019-09-30 | -$4.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $414.00K 10-Q · filed 2020-11-12 | ||
| 2019-06-30 | $418.00K 10-Q · filed 2020-08-27 | |||
| 2018-12-31 | $932.00K 10-K · filed 2021-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |